PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
Objective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS). Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Avicenna Tajik State Medical University
2024-03-01
|
Series: | Паёми Сино |
Subjects: | |
Online Access: | https://doi.org/10.25005/2074-0581-2024-26-1-10-17 |
_version_ | 1797234929594007552 |
---|---|
author | L.A. SHPAGINA I.S. SHPAGIN L.D. KHIDIROVA A.A. VASILENKO |
author_facet | L.A. SHPAGINA I.S. SHPAGIN L.D. KHIDIROVA A.A. VASILENKO |
author_sort | L.A. SHPAGINA |
collection | DOAJ |
description | Objective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS).
Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The duration of AH was 5.6±0.2 years. Among them 73 patients and a history of COVID-19 infection (confirmed SARS-CoV-2 infection; duration more than 12 weeks) with subsequent development of PCS, while 61 patients did not have a history of COVID-19. Patients with PCS which were diagnosed with depressive syndrome, were further divided into two subgroups depending on agomelatine intake (those who received this medication and those who refused). A general clinical examination and psychodiagnostics were carried out using validated methods, such as HADS and SPMSQ. Statistical analysis was carried out in the RStudio program.
Results: Based on the HADS questionnaire, patients with PCS demonstrated a higher rate of depressive syndrome compared to the patients without a history of COVID-19 (41% vs. 12%, p<0.001). Based on the severity of depressive syndrome, the following rates were found in the groups: subclinically expressed depression – in 26% of patients with PCS vs. 12% of patients without COVID-19 (p<0.001), clinically pronounced depression (only in the group of patients with PCS) – in 15% (p=0.007). Additionally, in patients with PCS psychocogniцtive function was assessed using SPMSQ questionnaire; among them those receiving agomelatine showed significantly less frequent and severe psychocognitive dysfunction compared to those who refuse the medication intake (32% vs. 94%, p=0.001).
Conclusion: Patients with PCS are characterized by a more severe manifestation of anxiety-depressive syndrome, and the use of agomelatine shows statistically significant effectiveness in this category of patients. |
first_indexed | 2024-04-24T16:39:52Z |
format | Article |
id | doaj.art-cf05532dfe254cf4b647d64e08160df3 |
institution | Directory Open Access Journal |
issn | 2074-0581 2959-6327 |
language | English |
last_indexed | 2024-04-24T16:39:52Z |
publishDate | 2024-03-01 |
publisher | Avicenna Tajik State Medical University |
record_format | Article |
series | Паёми Сино |
spelling | doaj.art-cf05532dfe254cf4b647d64e08160df32024-03-29T10:59:32ZengAvicenna Tajik State Medical UniversityПаёми Сино2074-05812959-63272024-03-01261101710.25005/2074-0581-2024-26-1-10-17PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROMEL.A. SHPAGINA0I.S. SHPAGIN1L.D. KHIDIROVA2A.A. VASILENKO3Novosibirsk State Medical University, Novosibirsk, Russian Federation. City Clinical Hospital № 2, Novosibirsk, Russian FederationNovosibirsk State Medical University, Novosibirsk, Russian Federation. City Clinical Hospital № 2, Novosibirsk, Russian FederationNovosibirsk State Medical University, Novosibirsk, Russian Federation. Novosibirsk Regional Clinical Cardiology Dispensary, Novosibirsk, Russian FederationNovosibirsk State Medical University, Novosibirsk, Russian Federation. City Clinical Hospital № 2, Novosibirsk, Russian FederationObjective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS). Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The duration of AH was 5.6±0.2 years. Among them 73 patients and a history of COVID-19 infection (confirmed SARS-CoV-2 infection; duration more than 12 weeks) with subsequent development of PCS, while 61 patients did not have a history of COVID-19. Patients with PCS which were diagnosed with depressive syndrome, were further divided into two subgroups depending on agomelatine intake (those who received this medication and those who refused). A general clinical examination and psychodiagnostics were carried out using validated methods, such as HADS and SPMSQ. Statistical analysis was carried out in the RStudio program. Results: Based on the HADS questionnaire, patients with PCS demonstrated a higher rate of depressive syndrome compared to the patients without a history of COVID-19 (41% vs. 12%, p<0.001). Based on the severity of depressive syndrome, the following rates were found in the groups: subclinically expressed depression – in 26% of patients with PCS vs. 12% of patients without COVID-19 (p<0.001), clinically pronounced depression (only in the group of patients with PCS) – in 15% (p=0.007). Additionally, in patients with PCS psychocogniцtive function was assessed using SPMSQ questionnaire; among them those receiving agomelatine showed significantly less frequent and severe psychocognitive dysfunction compared to those who refuse the medication intake (32% vs. 94%, p=0.001). Conclusion: Patients with PCS are characterized by a more severe manifestation of anxiety-depressive syndrome, and the use of agomelatine shows statistically significant effectiveness in this category of patients.https://doi.org/10.25005/2074-0581-2024-26-1-10-17anxiety-depressive syndromedepressionagomelatinevaldoxanpost-covid syndromecovid-19arterial hypertension. |
spellingShingle | L.A. SHPAGINA I.S. SHPAGIN L.D. KHIDIROVA A.A. VASILENKO PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME Паёми Сино anxiety-depressive syndrome depression agomelatine valdoxan post-covid syndrome covid-19 arterial hypertension. |
title | PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME |
title_full | PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME |
title_fullStr | PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME |
title_full_unstemmed | PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME |
title_short | PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME |
title_sort | psychocognitive status of patients with arterial hypertension combined with post covid syndrome |
topic | anxiety-depressive syndrome depression agomelatine valdoxan post-covid syndrome covid-19 arterial hypertension. |
url | https://doi.org/10.25005/2074-0581-2024-26-1-10-17 |
work_keys_str_mv | AT lashpagina psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome AT isshpagin psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome AT ldkhidirova psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome AT aavasilenko psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome |